CA2347331C - Freeze-dried composite materials and processes for the production thereof - Google Patents
Freeze-dried composite materials and processes for the production thereof Download PDFInfo
- Publication number
- CA2347331C CA2347331C CA2347331A CA2347331A CA2347331C CA 2347331 C CA2347331 C CA 2347331C CA 2347331 A CA2347331 A CA 2347331A CA 2347331 A CA2347331 A CA 2347331A CA 2347331 C CA2347331 C CA 2347331C
- Authority
- CA
- Canada
- Prior art keywords
- collagen
- sponge
- freeze
- dried
- regenerated cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/043—Proteins; Polypeptides; Degradation products thereof
- A61L31/044—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/90—Negative pressure wound therapy devices, i.e. devices for applying suction to a wound to promote healing, e.g. including a vacuum dressing
- A61M1/91—Suction aspects of the dressing
- A61M1/915—Constructional details of the pressure distribution manifold
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2209/00—Ancillary equipment
- A61M2209/02—Equipment for testing the apparatus
Abstract
The invention provides a sterile freeze-dried sponge, wherein at least 80% by weight of the sponge consists of collagen and oxidized regenerated cellulose in the weight ratio 60:40 to 40:60, wherein the sponge has a dry tensile strength of more than 3N and/or a wet tensile strength of more than 1 N. Preferably, the collagen has a degree of denaturation less than 20% and the sponge is substantially free of chemical cross-links. The invention also provides methods for the manufacture of sponges according to the invention
Description
FREEZE-DRIED COMPOSITE MATERIALS AND PROCESSES FOR THE
PRODUCTION THEREOF
Field s The present invention relates to freeze-dried pads comprising a major fraction of a mixture of collagen and oxidized regenerated cellulose (ORC), and to processes for the production of such pads.
Back rg ound W098/00180 describes the use of freeze-dried sponges of collagen admixed with io oxidized regenerated cellulose (ORC) for the treatment of chronic wounds.
Such sponges must in practice meet stringent requirements of purity, sterility and non--antigenicity.
It has not hitherto been possible to provide sponges of collagen/ORC mixtures having high reproducibility and high tensile strength both when wet and when dry.
is In particular, collagen is prone to denaturation when it is sterilized by gamma--irradiation. Furthermore, collagen sponges tend to disintegrate rather rapidly in wound fluid, especially in the presence of collagenase enzymes. Whilst this problem can be diminished by chemical cross-linking of the collagen sponge using cross-linking agents such as glutaldehyde, the use of such cross-linking 2o agents can give rise to problems of toxicity and antigenicity.
Summary of the Invention Accordingly, it is an object of the present invention to provide physiologically acceptable, sterile sponge pads based on collagen/ORC mixtures that exhibit high tensile strength.
It is a further object of the present invention to provide physiologically acceptable, sterile sponge pads based on collagen/ORC mixtures that have very high purity, sterility and low bioburden.
s It is a further object of the present invention to provide physiologically acceptable, sterile sponge pads based on collagen/ORC mixtures that have high uniformity.
It is a further object of the present invention to provide physiologically acceptable, sterile sponge pads based on collagen/ORC mixtures that exhibit reduced resorption rates under simulated physiological conditions.
io It is a further object of the present invention to provide physiologically acceptable, sterile sponge pads based on collagen/ORC mixtures that exhibit high mechanical strength and long resorption times without chemical cross-linking.
The present invention provides a sterile freeze-dried sponge, wherein at least 80% by weight of the sponge consists of a mixture of collagen and oxidized is regenerated cellulose in the weight ratio 60:40 to 40:60, and wherein thE~
sponge has a dry tensile strength as herein defined of more than 3N.
The freeze-dried sponge pad is sterile. Preferably, the sterility assurance level is better than 10-6. Preferably, the sponge has been sterilized by gamma-irradiation.
The sponge comprises at least 80% by weight of a mixture of collagen and ORC
2o in the rate ratio 60:40 to 40:60. Preferably, the weight ratio contains a small excess of collagen, in a range 50:50 to 40:60 ORC:collagen. Preferably, the freeze-dried sponge consists essentially of collagen, ORC, water and up to 5%
of one or more therapeutically active substances such as growth factors.
Preferably, the freeze-dried sponge contains no more than 1 % by weight of constituents 2s other than collagen, ORC and water.
The collagen content is determined by hydrolysing the collagen into its constituent amino acids and analyzing for hydroxyproline as detailed below.
The collagen content is calculated to be 7.19 times the hydroxyproline content.
The ORC content is determined by hydrolyzing it to its constituent monosaccharides and analyzing for glucuronic acid as detailed farther below.
s Preferably, the freeze-dried sponge has a pH, measured as hereinafter described, of from 2.3 to 4.0, preferably from 2.5 to 3Ø
Preferably, the sterile freeze-dried sponges according to the present invention have a degree of collagen denaturation, measured as hereinafter described, of io less than 15%, preferably less than 10%, and more preferably less than 5%.
It is a particularly advantageous feature of the freeze-dried sponges according to the present invention that the collagen is stabilized against denaturation by the gamma-irradiation used in the sterilizing. The degree of denaturation of the collagen is determined by treatment with trypsin to dissolve the denatured is collagen (trypsin does not dissolve native collagen), followed by filtration and quantitation of the hydroxyproline in the filtrate, as detailed further below.
The sterile freeze-dried sponges according to the present invention preferably have a dry tensile strength (maximum load measured as hereinafter dE;scribed) 2o greater than 3N, preferably greater than 4N. Preferably, the dry tensilE~
load at 20% extension, measured as hereinafter described, is greater than 2.5N, preferably greater than 3.5N. Preferably, the dry extension at break, measured as hereinafter described, is from 15 to 30%, preferably from 20 to 25%.
2s The tensile strength characteristics of the sponges according to the present invention are further characterised by wet strength measurements on samples that have been soaked for 15 minutes in PBS prior to testing. The resulting wet strength maximum load is preferably greater than 1 N, more preferably greater than 1.25N. The wet load at 20% extension is greater than 0.1 N, preferably 3o greater than 0.2N, most preferably 0.2-0.3N. The wet extension at break is preferably 75-100%, more preferably 80-90%.
PRODUCTION THEREOF
Field s The present invention relates to freeze-dried pads comprising a major fraction of a mixture of collagen and oxidized regenerated cellulose (ORC), and to processes for the production of such pads.
Back rg ound W098/00180 describes the use of freeze-dried sponges of collagen admixed with io oxidized regenerated cellulose (ORC) for the treatment of chronic wounds.
Such sponges must in practice meet stringent requirements of purity, sterility and non--antigenicity.
It has not hitherto been possible to provide sponges of collagen/ORC mixtures having high reproducibility and high tensile strength both when wet and when dry.
is In particular, collagen is prone to denaturation when it is sterilized by gamma--irradiation. Furthermore, collagen sponges tend to disintegrate rather rapidly in wound fluid, especially in the presence of collagenase enzymes. Whilst this problem can be diminished by chemical cross-linking of the collagen sponge using cross-linking agents such as glutaldehyde, the use of such cross-linking 2o agents can give rise to problems of toxicity and antigenicity.
Summary of the Invention Accordingly, it is an object of the present invention to provide physiologically acceptable, sterile sponge pads based on collagen/ORC mixtures that exhibit high tensile strength.
It is a further object of the present invention to provide physiologically acceptable, sterile sponge pads based on collagen/ORC mixtures that have very high purity, sterility and low bioburden.
s It is a further object of the present invention to provide physiologically acceptable, sterile sponge pads based on collagen/ORC mixtures that have high uniformity.
It is a further object of the present invention to provide physiologically acceptable, sterile sponge pads based on collagen/ORC mixtures that exhibit reduced resorption rates under simulated physiological conditions.
io It is a further object of the present invention to provide physiologically acceptable, sterile sponge pads based on collagen/ORC mixtures that exhibit high mechanical strength and long resorption times without chemical cross-linking.
The present invention provides a sterile freeze-dried sponge, wherein at least 80% by weight of the sponge consists of a mixture of collagen and oxidized is regenerated cellulose in the weight ratio 60:40 to 40:60, and wherein thE~
sponge has a dry tensile strength as herein defined of more than 3N.
The freeze-dried sponge pad is sterile. Preferably, the sterility assurance level is better than 10-6. Preferably, the sponge has been sterilized by gamma-irradiation.
The sponge comprises at least 80% by weight of a mixture of collagen and ORC
2o in the rate ratio 60:40 to 40:60. Preferably, the weight ratio contains a small excess of collagen, in a range 50:50 to 40:60 ORC:collagen. Preferably, the freeze-dried sponge consists essentially of collagen, ORC, water and up to 5%
of one or more therapeutically active substances such as growth factors.
Preferably, the freeze-dried sponge contains no more than 1 % by weight of constituents 2s other than collagen, ORC and water.
The collagen content is determined by hydrolysing the collagen into its constituent amino acids and analyzing for hydroxyproline as detailed below.
The collagen content is calculated to be 7.19 times the hydroxyproline content.
The ORC content is determined by hydrolyzing it to its constituent monosaccharides and analyzing for glucuronic acid as detailed farther below.
s Preferably, the freeze-dried sponge has a pH, measured as hereinafter described, of from 2.3 to 4.0, preferably from 2.5 to 3Ø
Preferably, the sterile freeze-dried sponges according to the present invention have a degree of collagen denaturation, measured as hereinafter described, of io less than 15%, preferably less than 10%, and more preferably less than 5%.
It is a particularly advantageous feature of the freeze-dried sponges according to the present invention that the collagen is stabilized against denaturation by the gamma-irradiation used in the sterilizing. The degree of denaturation of the collagen is determined by treatment with trypsin to dissolve the denatured is collagen (trypsin does not dissolve native collagen), followed by filtration and quantitation of the hydroxyproline in the filtrate, as detailed further below.
The sterile freeze-dried sponges according to the present invention preferably have a dry tensile strength (maximum load measured as hereinafter dE;scribed) 2o greater than 3N, preferably greater than 4N. Preferably, the dry tensilE~
load at 20% extension, measured as hereinafter described, is greater than 2.5N, preferably greater than 3.5N. Preferably, the dry extension at break, measured as hereinafter described, is from 15 to 30%, preferably from 20 to 25%.
2s The tensile strength characteristics of the sponges according to the present invention are further characterised by wet strength measurements on samples that have been soaked for 15 minutes in PBS prior to testing. The resulting wet strength maximum load is preferably greater than 1 N, more preferably greater than 1.25N. The wet load at 20% extension is greater than 0.1 N, preferably 3o greater than 0.2N, most preferably 0.2-0.3N. The wet extension at break is preferably 75-100%, more preferably 80-90%.
Preferably, the sterile freeze-dried sponges according to the present invention are not chemically cross-linked. They may have some dehydrothermal cross-linking as a result of the freeze-drying process, but preferably there is no s chemical cross-linking by glutaldehyde or the like. This reduces the antigenicity and processing costs of the sponges. The present invention achieves satisfactory physical properties of the sponges and sufficiently long resorption times in vivo by very careful control of the composition and manufacturing conditions of the sponges. In particular, the sponges preferably contain ORC fibers, wherein a io volume fraction of at least 80% of the fibers have lengths in the range of 20Nm to 1000Nm. Such a size distribution can be achieved, for example, by milling an ORC cloth, followed sieving the milled powder to remove fibers outside the range.
Preferably, the average (mean by volume) length of the ORC fibers is in the range 250Nm to 450Nm.
is The selection of ORC fiber lengths in this range results in easy mixing of the ORC and collagen and highly homogeneous products. The ORC is more thoroughly complexed with the collagen, which results in enhanced thE~rapeutic properties of the sponge. Furthermore, the ORC is more effective to reduce denaturation of the collagen by gamma-radiation during sterilization.
Surprisingly, 2o these advantages can be achieved while maintaining the tensile strength of the sponge despite the small size of the ORC fibers.
The desired physicochemical properties of the freeze-dried sponges according to the present invention are further achieved by the use of collagen 'that has undergone sequential alkali and acid treatment steps to purify the collagen 25 substantially without denaturing the collagen fibers. Preferably, the bioburden (TVC) of the freeze-dried sponge according to the present invention is less than 100cfu/g, more preferably less than l0cfu/g, and most preferably IEas than 1 cfu/g.
The sterile freeze-dried sponges according to the present invention have high 3o and uniform porosity, and a high liquid absorption capacity. The measured absorption of the uncompressed pads in 0.9% saline is preferably greater than 12g/100cm2, more preferably greater than 15g/100cm2.
Preferably, the average (mean by volume) length of the ORC fibers is in the range 250Nm to 450Nm.
is The selection of ORC fiber lengths in this range results in easy mixing of the ORC and collagen and highly homogeneous products. The ORC is more thoroughly complexed with the collagen, which results in enhanced thE~rapeutic properties of the sponge. Furthermore, the ORC is more effective to reduce denaturation of the collagen by gamma-radiation during sterilization.
Surprisingly, 2o these advantages can be achieved while maintaining the tensile strength of the sponge despite the small size of the ORC fibers.
The desired physicochemical properties of the freeze-dried sponges according to the present invention are further achieved by the use of collagen 'that has undergone sequential alkali and acid treatment steps to purify the collagen 25 substantially without denaturing the collagen fibers. Preferably, the bioburden (TVC) of the freeze-dried sponge according to the present invention is less than 100cfu/g, more preferably less than l0cfu/g, and most preferably IEas than 1 cfu/g.
The sterile freeze-dried sponges according to the present invention have high 3o and uniform porosity, and a high liquid absorption capacity. The measured absorption of the uncompressed pads in 0.9% saline is preferably greater than 12g/100cm2, more preferably greater than 15g/100cm2.
Preferably, the sterile freeze-dried sponge according to the present invention has a resorption time under simulated physiological conditions as described in more detail below of more than 48 hours.
s The present invention further provides a method of manufacture of a freeze-dried sponge pad comprising the steps of:-providing an acidified paste of purified collagen fibers, wherein the collagen is less than 10% denatured;
providing oxidized regenerated cellulose fibers, wherein at least 80% of io said fibers have lengths in the range of 20Nm to 1000Nm;
combining said collagen and said ORC fibers in a homogeneous aqueous dispersion in a weight ratio of 60:40 to 40:60 collagen:ORC, said aqueous dispersion being acidified to a pH in the range of 2.8 to 3.2 and having a total solids concentration of 0.8 to 1.2% by weight;
Is pouring said aqueous dispersion into trays to a depth greater than 1 cm;
freezing the dispersion to a temperature less than -30°C, followed by a temperature programmed freeze drying and dehydrothermal cross-linking to a final moisture content of 5-15% by weight;
splitting the freeze-dried dispersion to remove surface layers and leave 20 one or more pads; and sterilizing the one or more pads by gamma-irradiation.
Preferably, the process according to the present invention is carried out substantially without the use of any chemical cross-linking agents.
Preferably, the step of providing collagen comprises the following steps:
providing fresh and unswollen splits of bovine corium;
2s treating the corium splits with a solution containing sodium hydroxide and hydrogen peroxide to swell and sterilize the corium; then treating the corium with a aqueous alkali solution at a pH greater' than 12 and temperature less than 50°C for a period of 10-14 days; then treating the corium with a aqueous acid solution at a pH of 0.8-~1.2 and temperature less than 50°C until the pH of the corium splits drops to less than 2.5; then s washing the corium, and comminuting the corium with sufficient water to form a paste.
This treatment results in a collagen of exceptional purity and uniformity, without significant denaturing of the collagen. The collagen paste may be stored in the frozen state, but preferably the collagen is not freeze-dried intermediate the io above steps and the step of combining the collagen with the ORC.
Preferably, the step of providing oxidized regenerated cellulose fibers comprising milling an oxidized regenerated cellulose cloth and screening the milled particles to remove particles having size less than 20Nm or greater than 1000Nm.
Preferably, the step of dispersing the collagen and the ORC comprises the steps Is of:-adding an acid-swollen collagen/water paste to acidified water;
adding oxidized regenerated cellulose fibers to the acidified water; and homogenizing the resulting mixture.
Detailed Description 2o The dispersion is poured into trays to a depth of at least 10 mm, preferably at least 20mm, and frozen into blocks in the trays before freeze drying. The freezing is preferably carried out by placing the trays containing the slurry onto pre-chilled shelves at -55°C. The trays are then loaded into a freeze-dryer, held at -~50°C for two hours, then at -40°C before starting the freeze-drying cycle. This freezing 2s method gives more uniformly distributed ice crystals, and hence more uniform products, than simply blast freezing the slurry in the trays.
Preferably, the step of freeze drying is carried out with dehydrothermal cross-linking using a temperature program in the range -40°C to +30°C, to give blocks of freeze dried material. The blocks are split to remove surface layers, and to provide one or more pads. The settling of collagen and ORC fibers in trays results in a desired orientation of collagen and ORC fibers in the final pads:
Furthermore, splitting the final pads from a larger block ensures that they have high homogeneity and surface uniformity.
Preferably, the step of sterilizing is carried out by gamma-irradiation at a dose of 18-29 KGy. It has been found that surprisingly little denaturation of the collagen takes place in the sterilizing step, which may be due to a stabilizing effect of the ORC.
In preferred embodiments of the process according to the present invention, the weight ratio of collagen to oxidized regenerated cellulose is from 50:50 to 55:45 and the pH of the aqueous dispersion is from 2.9 to 3.1.
A specific embodiment of the process and product according to the present invention will now be described further, by way of example.
Example 1 A freeze-dried collagen/ORC sponge is prepared as follows.
First, the collagen component is prepared from bovine corium as follows.
Bovine corium is split from cow hide, scraped and soaked in sodium hypochlorite solution (0.03% wlv) to inhibit microbial activity pending further processing.
The corium is then washed with water and treated with a solution containing sodium hydroxide (0.2% w/v) and hydrogen peroxide (0.02% w/v) to swell and sterilize the corium at ambient temperature.
The corium splits then undergo an alkali treatment step in a solution containing sodium hydroxide, calcium hydroxide and sodium bicarbonate (0.4% w/v, 0.6% w/v and 0.05% w.v, respectively) at pH greater than 12.2, ambient temperature, and for a time of 10-14 days, with tumbling, until an amide nitrogen level less than 0.24mmol/g is reached.
The corium splits then undergo an acid treatment step with 1 % hydrochloric acid at ambient temperature and pH 0.8-1.2. The treatment is continued with tumbling until the corium splits have absorbed sufficient acid to reach a pH less than 2.5.
The splits are then washed with water until the pH value of corium splits reaches 3.0-3.4.
The corium splits are then comminuted with ice in a bowl chopper first with a coarse comminution and then with a fine comminution setting. The resulting paste, which is made up in a ratio of 650g of the corium splits to 1008 of water, as ice, is frozen and stored before use in the next stage of the process.
However, the collagen is not freeze-dried before admixture with the ORC in the next stage.
The ORC component of the freeze-dried pad is prepared as follows. A
SURGICEL cloth (Johnson & Johnson Medical, Arlington) is milled using a rotary knife cutter through a screen-plate, maintaining the temperature below 60°C.
The milled ORC powder and the required weight (according to solids content) of frozen collagen paste are then added to a sufficient amount of water acidified with acetic acid to obtain a pH value of 3.0 and a total solids content of 1.0%.
The mixture is homogenized through a Fryma MZ130D homogenizer, pto~ressively diminishing the settings to form a homogeneous slurry. The p! ~ of the slurry is maintained at 2.9-3.1. The slurry temperature is maintained below 20°C, and the solids content is maintained at 1 % t 0.07.
The resulting slurry is pumped to a degassing vessel. Vacuum is initiated for a minimum of 30 minutes, with intermittent stirring, to degas the slurry. The slurry is then pumped into freeze-drier trays to a depth of 25mm. The trays are placed onto freezer shelves where the temperature has been preset to -40°C.
The freeze-drier programme is then initiated to dry and dehydrothermally cross-link the collagen and ORC to form thick sponge pads.
_g_ On completion of the cycle, the vacuum is released, the freeze-dried blocks are removed, and are then split to remove the top and bottom surface layers, and to divide the remainder of the blocks into 3mm-thick pads. The step of splitting the freeze-dried blocks into pads is carried out with a Fecken Kirfel K1 slitter.
Finally, the pads are die-cut to the desired size and shape on a die-cutter, packaged, and sterilized with 18-29 KGy of cobalt 60 gamma-irradiation.
Surprisingly, this irradiation does not cause significant denaturation of the collagen, which appears to be stabilized by the presence of ORC.
The resulting freeze-dried collagen ORC pads have a uniform, white, velvety appearance. The thickness of the pads is 3.2 ~ 0.17mm (N = 8 batches). The collagen content is 54% ~ 3.8% (N = 12 batches). The hydroxyproline content is 7.6 t 0.5% (N = 12 batches). The carboxylate content is 10.98 t 0.81 % {N = 12 batches). The ash content is 0.16 t 0.1 % (N = 12 batches). The heavy metals (lead) content is less than 1 ppm. The pH is 2.78 t 0.15. The denaturation level is 4.87 t 1.54%. The endotoxin level is 33.5 t 0.9 cfu/g. The bioburden level is 0.2 ~ 0.3 cfu/g. The moisture content {loss on drying) is 12.0 t 12.8%.
Procedure 1 The collagen content of the materials according to the present invention is measured as follows:-Briefly, collagen is hydrolysed into constituent amino acids. The amount of the amino acid hydroxyproline is determined by oxidizing with chloramine-T and then coupling with 4-dimethylamino-benzaldehyde to produce a coloured product, the concentration of which is measured spectophotometrically at 550 nanometers.
Hydrolysis of the samples is carried out with 6 molar hydrochloric acid at 105°C
until digestion is completed, which takes at least 16 hours. The solution is then neutralized to pH 6 with 6 molar NaOH solution. The solution is then diluted.
Typically, for a 10 mg sample, the procedure uses 1 ml of 6 molar HCI, and the final volume for analysis on dilution is 500 ml.
A 1.0 ml sample of the test solution is treated with 1.0 ml of an oxidant solution prepared by dissolving 7 gm of chloramine-T in 600 ml of citrate buffer. The mixture is allowed to stand for 10 minutes, after which 1.0 ml of 20%
perchloric acid is added, mixed and allowed to stand for 5 minutes at room temperature.
The mixture is then treated with 1.0 ml of a colour reagent prepared by dissolving 30 gm of 4-dimethylamino benzaldehyde in 45 ml of perchloric acid (60% wlv) followed by dilution in 250 ml of propane-2-ol. The mixture was treated in a water bath at 60°C for 20 minutes, cooled for 5 minutes, followed by reading the optical density at 550 nanometers. The optical density is compared against values measured for control samples of pure collagen at various concentrations, pure hydroxyproline at various concentrations, and blank control samples to arrive at the hydroxyproline content.
The collagen content of the sample in weight percent is obtained by multiplying the measured hydroxyproline content in weight percent by 7.19.
Procedure 2 The amount of denatured collagen present in the materials according to the present invention is determined as follows.
Briefly, native collagen is protected by its triple-helical structure against proteolytic enzymes except for specific collagenases. If the helical structure is damaged, the resulting denatured collagen is susceptible to other proteases, such as trypsin, and is degraded to peptides. In this procedure, trypsin-resistant native collagen is separated from the degraded peptides by salt precipitation, and non-native collagen present in the filtrate is quantitated by hydroxyproline analysis.
A sample of the material according to the invention (100 mg) is weighed into a 50 ml conical flask. To the flask is added 10 ml of tris-HCI buffer solution containing 500 units trypsin. Blank experiments without the trypsin enzyme are also run. The mixtures are shaken at 4°C for 5 hours. Then 2.5 ml of 25% NACI
in 3 molar acetic acid are added to each container and mixed thoroughly. The containers are then placed in a refrigerator at 4°C for a minimum of 16 hours. The chilled extract is filtered through Whatman 541 filter paper into 50 ml beaker, and the hydroxyproline content of the sample of the filtrate is measured by the method according to Procedure 1. Denatured collagen is calculated as 7.19 x the measured hydroxyproline level, and the percentage of denatured collagen is calculated by comparison with the total collagen content measured by Procedure 1.
Procedure 3 The ORC content of materials according to the present invention is measured by a method similar to that described by Bitter and Muir in Anal~~tical Chemistry vol. 4 (1962), pages 300-334.
Briefly, the material is hydrolysed to its individual constituents using sulphuric acid.
Upon hydrolysis, the ORC breaks down to glucuronic acid (approximately 80%) and glucose (20%). The glucuronic acid residues then undergo a colour reaction with carbozole, the absorbance of which is measured against a series of ORC
standards to give an estimation of the ORC content.
Samples of the material under test (10 mg) are placed in hydrolysate tubes. De-ionised water (0.5 ml) and concentrated sulphuric acid (3 ml) are added, and the mixture is mixed on a vortex mixer for 15 minutes and checked for complete dissolution of the sample.
An aliquot (0.1 ml) of each sample hydrolysate is added to 2.9 ml of sodium tetraborate solution (0.025 molar in concentrated sulphuric acid) and mixed using vortex mixer. The sample tubes are placed in a boiling water bath for 10 minutes, and then cooled. Then 0.1 ml of carbozole solution (0.125% in ethanol) is added to each tube and mixed thoroughly with a vortex mixer, followed by placing the tubes in a boiling water bath for 15 minutes and cooling. The absorbance of the resulting solutions at 523 nanometers is then measured against a zero concentration ORC standard.
Procedure 4 The number of bacteria, fungi or yeast organisms present in the materials according to the present invention is measured as follows.
A 2 gm sample of the material is extracted with 100 ml of sterile one-quarter strength Ringer's solution, and an aliquot (5 ml) is passed to a sterile membrane filter (pore size 0.45 m) for sterile filtration. The filters are placed onto a nutrient medium in a Petri dish, and incubated under sterile conditions for 48 hours at 30°C
to allow the growth of germ colonies which can be counted with the naked eye or under a stereomicroscope if necessary. Appropriate control blanks are also run.
The level of microbiological contamination of the samples is expressed as the total viable count (TVC) in colony forming units per gram (cfu/g) in accordance with the following formula:
TVC = [(N x 100)/(5 x W)]
where N is the count of colonies, W is the weight of the sample in grams, 100 is the volume of the extractant solution in ml, and 5 is the volume of the aliquot (5ml) that is filtered.
Procedure 5 The wet and dry tensile strengths of the material according to the invention are measured as follows.
Samples are die cut from a 3mm thickness pad of the material. The sample dimensions are 2.5 x 12 cm. The samples are loaded into an Instron tensile tester with jaw face dimensions 50 x 25 ml. The dry tensile strength is measured as the load at 20% elongation and the load at break. The extension at break is expressed as the percentage of the initial jaw separation: A minimum of 5 specimens was tested.
The wet tensile measurements are carried out in the same way on samples that have been soaked for 15 minutes in phosphate buffered saline (PBS).
Procedure 6 The pH of solid materials according to the present invention is measured by macerating 100 gm of the material in 100 ml of deionised water, and measuring the pH of the resulting slurry with a glass electrode.
Procedure 7 The resorption rate of the composite materials according to the invention is measured in a flow of simulated wound fluid as follows.
A circular pad of the material under test, of thickness 3mm and diameter 6cm is placed in a cylindrical recess and covered with a layer of liquid-impermeable backing material. Simulated wound fluid (3.45 mg/l collagenase in phosphate buffered saline) was pumped radially at a rate of 2.5 ml, 7.5 ml or 12 ml/24 hours from an opening below the centre of the disk under test to six openings disposed radially around the edges of the disk under test, below the disk under test, to simulate low, medium and high wound exudate flow rates. The time to resorption was estimated as the time required for complete dissolution of the pad under test.
This time was at least two days for the high flow rate, at least three days for the medium flow rate, and at least six days for the low flow rate.
Procgdure 8 The liquid absorbency of the materials according to the present invention was measured as follows.
A sample (typically 2.5 cm x 2.5 cm x 0.3 cm) of the material under test was weighed dry, and then immersed in phosphate buffered saline (PBS) for 15 minutes, removed with tweezers, and weighed again. The liquid absorbency was then calculated in grams of absorbed liquid per gram (dry weight) of the material.
Procedure 9 The levels of bacterial endotoxin in the materials according to the present invention are determined as follows.
Briefly, endotoxins from gram-negative bacterial cell walls cause limulus I S amebocyte lysate (LAL) to gel. The test is conducted as a limit test, wherein the sample is determined to be positive or negative to the test, judged against pre-established endotoxin concentrations. Positive and negative controls are essential and are carried out with each test run. The control standard endotoxin has its potency verified against referenced standard endotoxin (USP EC6). Details of the method can be found in Carl Freudenberg Method 091,102 (pyrogenicity); in USP
XXIII (1985); in the FDA Guidelines 1987 and in European Pharmacoepia 2.6.14 ( 1998 ).
The embodiment of Example 1 has been described by wad of example only. Many other compositions and methods falling with the scope of the present invention will be apparent to the skilled reader.
s The present invention further provides a method of manufacture of a freeze-dried sponge pad comprising the steps of:-providing an acidified paste of purified collagen fibers, wherein the collagen is less than 10% denatured;
providing oxidized regenerated cellulose fibers, wherein at least 80% of io said fibers have lengths in the range of 20Nm to 1000Nm;
combining said collagen and said ORC fibers in a homogeneous aqueous dispersion in a weight ratio of 60:40 to 40:60 collagen:ORC, said aqueous dispersion being acidified to a pH in the range of 2.8 to 3.2 and having a total solids concentration of 0.8 to 1.2% by weight;
Is pouring said aqueous dispersion into trays to a depth greater than 1 cm;
freezing the dispersion to a temperature less than -30°C, followed by a temperature programmed freeze drying and dehydrothermal cross-linking to a final moisture content of 5-15% by weight;
splitting the freeze-dried dispersion to remove surface layers and leave 20 one or more pads; and sterilizing the one or more pads by gamma-irradiation.
Preferably, the process according to the present invention is carried out substantially without the use of any chemical cross-linking agents.
Preferably, the step of providing collagen comprises the following steps:
providing fresh and unswollen splits of bovine corium;
2s treating the corium splits with a solution containing sodium hydroxide and hydrogen peroxide to swell and sterilize the corium; then treating the corium with a aqueous alkali solution at a pH greater' than 12 and temperature less than 50°C for a period of 10-14 days; then treating the corium with a aqueous acid solution at a pH of 0.8-~1.2 and temperature less than 50°C until the pH of the corium splits drops to less than 2.5; then s washing the corium, and comminuting the corium with sufficient water to form a paste.
This treatment results in a collagen of exceptional purity and uniformity, without significant denaturing of the collagen. The collagen paste may be stored in the frozen state, but preferably the collagen is not freeze-dried intermediate the io above steps and the step of combining the collagen with the ORC.
Preferably, the step of providing oxidized regenerated cellulose fibers comprising milling an oxidized regenerated cellulose cloth and screening the milled particles to remove particles having size less than 20Nm or greater than 1000Nm.
Preferably, the step of dispersing the collagen and the ORC comprises the steps Is of:-adding an acid-swollen collagen/water paste to acidified water;
adding oxidized regenerated cellulose fibers to the acidified water; and homogenizing the resulting mixture.
Detailed Description 2o The dispersion is poured into trays to a depth of at least 10 mm, preferably at least 20mm, and frozen into blocks in the trays before freeze drying. The freezing is preferably carried out by placing the trays containing the slurry onto pre-chilled shelves at -55°C. The trays are then loaded into a freeze-dryer, held at -~50°C for two hours, then at -40°C before starting the freeze-drying cycle. This freezing 2s method gives more uniformly distributed ice crystals, and hence more uniform products, than simply blast freezing the slurry in the trays.
Preferably, the step of freeze drying is carried out with dehydrothermal cross-linking using a temperature program in the range -40°C to +30°C, to give blocks of freeze dried material. The blocks are split to remove surface layers, and to provide one or more pads. The settling of collagen and ORC fibers in trays results in a desired orientation of collagen and ORC fibers in the final pads:
Furthermore, splitting the final pads from a larger block ensures that they have high homogeneity and surface uniformity.
Preferably, the step of sterilizing is carried out by gamma-irradiation at a dose of 18-29 KGy. It has been found that surprisingly little denaturation of the collagen takes place in the sterilizing step, which may be due to a stabilizing effect of the ORC.
In preferred embodiments of the process according to the present invention, the weight ratio of collagen to oxidized regenerated cellulose is from 50:50 to 55:45 and the pH of the aqueous dispersion is from 2.9 to 3.1.
A specific embodiment of the process and product according to the present invention will now be described further, by way of example.
Example 1 A freeze-dried collagen/ORC sponge is prepared as follows.
First, the collagen component is prepared from bovine corium as follows.
Bovine corium is split from cow hide, scraped and soaked in sodium hypochlorite solution (0.03% wlv) to inhibit microbial activity pending further processing.
The corium is then washed with water and treated with a solution containing sodium hydroxide (0.2% w/v) and hydrogen peroxide (0.02% w/v) to swell and sterilize the corium at ambient temperature.
The corium splits then undergo an alkali treatment step in a solution containing sodium hydroxide, calcium hydroxide and sodium bicarbonate (0.4% w/v, 0.6% w/v and 0.05% w.v, respectively) at pH greater than 12.2, ambient temperature, and for a time of 10-14 days, with tumbling, until an amide nitrogen level less than 0.24mmol/g is reached.
The corium splits then undergo an acid treatment step with 1 % hydrochloric acid at ambient temperature and pH 0.8-1.2. The treatment is continued with tumbling until the corium splits have absorbed sufficient acid to reach a pH less than 2.5.
The splits are then washed with water until the pH value of corium splits reaches 3.0-3.4.
The corium splits are then comminuted with ice in a bowl chopper first with a coarse comminution and then with a fine comminution setting. The resulting paste, which is made up in a ratio of 650g of the corium splits to 1008 of water, as ice, is frozen and stored before use in the next stage of the process.
However, the collagen is not freeze-dried before admixture with the ORC in the next stage.
The ORC component of the freeze-dried pad is prepared as follows. A
SURGICEL cloth (Johnson & Johnson Medical, Arlington) is milled using a rotary knife cutter through a screen-plate, maintaining the temperature below 60°C.
The milled ORC powder and the required weight (according to solids content) of frozen collagen paste are then added to a sufficient amount of water acidified with acetic acid to obtain a pH value of 3.0 and a total solids content of 1.0%.
The mixture is homogenized through a Fryma MZ130D homogenizer, pto~ressively diminishing the settings to form a homogeneous slurry. The p! ~ of the slurry is maintained at 2.9-3.1. The slurry temperature is maintained below 20°C, and the solids content is maintained at 1 % t 0.07.
The resulting slurry is pumped to a degassing vessel. Vacuum is initiated for a minimum of 30 minutes, with intermittent stirring, to degas the slurry. The slurry is then pumped into freeze-drier trays to a depth of 25mm. The trays are placed onto freezer shelves where the temperature has been preset to -40°C.
The freeze-drier programme is then initiated to dry and dehydrothermally cross-link the collagen and ORC to form thick sponge pads.
_g_ On completion of the cycle, the vacuum is released, the freeze-dried blocks are removed, and are then split to remove the top and bottom surface layers, and to divide the remainder of the blocks into 3mm-thick pads. The step of splitting the freeze-dried blocks into pads is carried out with a Fecken Kirfel K1 slitter.
Finally, the pads are die-cut to the desired size and shape on a die-cutter, packaged, and sterilized with 18-29 KGy of cobalt 60 gamma-irradiation.
Surprisingly, this irradiation does not cause significant denaturation of the collagen, which appears to be stabilized by the presence of ORC.
The resulting freeze-dried collagen ORC pads have a uniform, white, velvety appearance. The thickness of the pads is 3.2 ~ 0.17mm (N = 8 batches). The collagen content is 54% ~ 3.8% (N = 12 batches). The hydroxyproline content is 7.6 t 0.5% (N = 12 batches). The carboxylate content is 10.98 t 0.81 % {N = 12 batches). The ash content is 0.16 t 0.1 % (N = 12 batches). The heavy metals (lead) content is less than 1 ppm. The pH is 2.78 t 0.15. The denaturation level is 4.87 t 1.54%. The endotoxin level is 33.5 t 0.9 cfu/g. The bioburden level is 0.2 ~ 0.3 cfu/g. The moisture content {loss on drying) is 12.0 t 12.8%.
Procedure 1 The collagen content of the materials according to the present invention is measured as follows:-Briefly, collagen is hydrolysed into constituent amino acids. The amount of the amino acid hydroxyproline is determined by oxidizing with chloramine-T and then coupling with 4-dimethylamino-benzaldehyde to produce a coloured product, the concentration of which is measured spectophotometrically at 550 nanometers.
Hydrolysis of the samples is carried out with 6 molar hydrochloric acid at 105°C
until digestion is completed, which takes at least 16 hours. The solution is then neutralized to pH 6 with 6 molar NaOH solution. The solution is then diluted.
Typically, for a 10 mg sample, the procedure uses 1 ml of 6 molar HCI, and the final volume for analysis on dilution is 500 ml.
A 1.0 ml sample of the test solution is treated with 1.0 ml of an oxidant solution prepared by dissolving 7 gm of chloramine-T in 600 ml of citrate buffer. The mixture is allowed to stand for 10 minutes, after which 1.0 ml of 20%
perchloric acid is added, mixed and allowed to stand for 5 minutes at room temperature.
The mixture is then treated with 1.0 ml of a colour reagent prepared by dissolving 30 gm of 4-dimethylamino benzaldehyde in 45 ml of perchloric acid (60% wlv) followed by dilution in 250 ml of propane-2-ol. The mixture was treated in a water bath at 60°C for 20 minutes, cooled for 5 minutes, followed by reading the optical density at 550 nanometers. The optical density is compared against values measured for control samples of pure collagen at various concentrations, pure hydroxyproline at various concentrations, and blank control samples to arrive at the hydroxyproline content.
The collagen content of the sample in weight percent is obtained by multiplying the measured hydroxyproline content in weight percent by 7.19.
Procedure 2 The amount of denatured collagen present in the materials according to the present invention is determined as follows.
Briefly, native collagen is protected by its triple-helical structure against proteolytic enzymes except for specific collagenases. If the helical structure is damaged, the resulting denatured collagen is susceptible to other proteases, such as trypsin, and is degraded to peptides. In this procedure, trypsin-resistant native collagen is separated from the degraded peptides by salt precipitation, and non-native collagen present in the filtrate is quantitated by hydroxyproline analysis.
A sample of the material according to the invention (100 mg) is weighed into a 50 ml conical flask. To the flask is added 10 ml of tris-HCI buffer solution containing 500 units trypsin. Blank experiments without the trypsin enzyme are also run. The mixtures are shaken at 4°C for 5 hours. Then 2.5 ml of 25% NACI
in 3 molar acetic acid are added to each container and mixed thoroughly. The containers are then placed in a refrigerator at 4°C for a minimum of 16 hours. The chilled extract is filtered through Whatman 541 filter paper into 50 ml beaker, and the hydroxyproline content of the sample of the filtrate is measured by the method according to Procedure 1. Denatured collagen is calculated as 7.19 x the measured hydroxyproline level, and the percentage of denatured collagen is calculated by comparison with the total collagen content measured by Procedure 1.
Procedure 3 The ORC content of materials according to the present invention is measured by a method similar to that described by Bitter and Muir in Anal~~tical Chemistry vol. 4 (1962), pages 300-334.
Briefly, the material is hydrolysed to its individual constituents using sulphuric acid.
Upon hydrolysis, the ORC breaks down to glucuronic acid (approximately 80%) and glucose (20%). The glucuronic acid residues then undergo a colour reaction with carbozole, the absorbance of which is measured against a series of ORC
standards to give an estimation of the ORC content.
Samples of the material under test (10 mg) are placed in hydrolysate tubes. De-ionised water (0.5 ml) and concentrated sulphuric acid (3 ml) are added, and the mixture is mixed on a vortex mixer for 15 minutes and checked for complete dissolution of the sample.
An aliquot (0.1 ml) of each sample hydrolysate is added to 2.9 ml of sodium tetraborate solution (0.025 molar in concentrated sulphuric acid) and mixed using vortex mixer. The sample tubes are placed in a boiling water bath for 10 minutes, and then cooled. Then 0.1 ml of carbozole solution (0.125% in ethanol) is added to each tube and mixed thoroughly with a vortex mixer, followed by placing the tubes in a boiling water bath for 15 minutes and cooling. The absorbance of the resulting solutions at 523 nanometers is then measured against a zero concentration ORC standard.
Procedure 4 The number of bacteria, fungi or yeast organisms present in the materials according to the present invention is measured as follows.
A 2 gm sample of the material is extracted with 100 ml of sterile one-quarter strength Ringer's solution, and an aliquot (5 ml) is passed to a sterile membrane filter (pore size 0.45 m) for sterile filtration. The filters are placed onto a nutrient medium in a Petri dish, and incubated under sterile conditions for 48 hours at 30°C
to allow the growth of germ colonies which can be counted with the naked eye or under a stereomicroscope if necessary. Appropriate control blanks are also run.
The level of microbiological contamination of the samples is expressed as the total viable count (TVC) in colony forming units per gram (cfu/g) in accordance with the following formula:
TVC = [(N x 100)/(5 x W)]
where N is the count of colonies, W is the weight of the sample in grams, 100 is the volume of the extractant solution in ml, and 5 is the volume of the aliquot (5ml) that is filtered.
Procedure 5 The wet and dry tensile strengths of the material according to the invention are measured as follows.
Samples are die cut from a 3mm thickness pad of the material. The sample dimensions are 2.5 x 12 cm. The samples are loaded into an Instron tensile tester with jaw face dimensions 50 x 25 ml. The dry tensile strength is measured as the load at 20% elongation and the load at break. The extension at break is expressed as the percentage of the initial jaw separation: A minimum of 5 specimens was tested.
The wet tensile measurements are carried out in the same way on samples that have been soaked for 15 minutes in phosphate buffered saline (PBS).
Procedure 6 The pH of solid materials according to the present invention is measured by macerating 100 gm of the material in 100 ml of deionised water, and measuring the pH of the resulting slurry with a glass electrode.
Procedure 7 The resorption rate of the composite materials according to the invention is measured in a flow of simulated wound fluid as follows.
A circular pad of the material under test, of thickness 3mm and diameter 6cm is placed in a cylindrical recess and covered with a layer of liquid-impermeable backing material. Simulated wound fluid (3.45 mg/l collagenase in phosphate buffered saline) was pumped radially at a rate of 2.5 ml, 7.5 ml or 12 ml/24 hours from an opening below the centre of the disk under test to six openings disposed radially around the edges of the disk under test, below the disk under test, to simulate low, medium and high wound exudate flow rates. The time to resorption was estimated as the time required for complete dissolution of the pad under test.
This time was at least two days for the high flow rate, at least three days for the medium flow rate, and at least six days for the low flow rate.
Procgdure 8 The liquid absorbency of the materials according to the present invention was measured as follows.
A sample (typically 2.5 cm x 2.5 cm x 0.3 cm) of the material under test was weighed dry, and then immersed in phosphate buffered saline (PBS) for 15 minutes, removed with tweezers, and weighed again. The liquid absorbency was then calculated in grams of absorbed liquid per gram (dry weight) of the material.
Procedure 9 The levels of bacterial endotoxin in the materials according to the present invention are determined as follows.
Briefly, endotoxins from gram-negative bacterial cell walls cause limulus I S amebocyte lysate (LAL) to gel. The test is conducted as a limit test, wherein the sample is determined to be positive or negative to the test, judged against pre-established endotoxin concentrations. Positive and negative controls are essential and are carried out with each test run. The control standard endotoxin has its potency verified against referenced standard endotoxin (USP EC6). Details of the method can be found in Carl Freudenberg Method 091,102 (pyrogenicity); in USP
XXIII (1985); in the FDA Guidelines 1987 and in European Pharmacoepia 2.6.14 ( 1998 ).
The embodiment of Example 1 has been described by wad of example only. Many other compositions and methods falling with the scope of the present invention will be apparent to the skilled reader.
Claims (22)
1. A sterile freeze-dried sponge, wherein at least 80% by weight of the sponge consists of a mixture of collagen and oxidized regenerated cellulose in the weight ratio 60:40 to 40:60, and wherein the sponge has a dry tensile strength as herein defined of more than 3N.
2. A sterile freeze-dried sponge, wherein at least 80% by weight of the sponge consists of a mixture of collagen and oxidized regenerated cellulose in the weight ratio 60:40 to 40:60, wherein the sponge has a wet tensile strength as herein defined greater than 1 N.
3. A sterile freeze-dried sponge according to claim 1, wherein the sponge is substantially free of chemical cross-links.
4. A sterile freeze-dried sponge according to claim 1, wherein the collagen has a degree of denaturation less than 20%.
5. A sterile freeze-dried sponge according to claim 5, wherein the collagen has a degree of denaturation less than 10%.
6. A sterile freeze-dried sponge according to claim 4, wherein 80% of the oxidized regenerated cellulose fibers by volume are between 20µm and 1000µm in length.
7. A sterile freeze-dried sponge according to claim 6, wherein the mean length of the oxidized regenerated cellulose fibers is from 250 to 450µm.
8. A sterile freeze-dried sponge according to claim 1, wherein the oxidized regenerated cellulose is in the form of fibers, and at least 90% of the fibers by volume are less than 1 mm in length.
9. A sterile freeze-dried sponge according to claim 1, wherein the ratio of collagen to oxidized regenerated cellulose is from 50:50 to 55:45.
10. A sterile freeze-dried sponge according to claim 1, wherein the bioburden (TVC) of the sponge is less than 100 cfu/g, preferably less-than 10 cfu/g, more preferably less than 1 cfu/g.
11. A sterile freeze-dried sponge according to claim 1, wherein the sponge contains from 5 to 15% by weight of water.
12. A sterile freeze-dried sponge according to claim 1, wherein a layer of the sponge of thickness 3mm has an uncompressed absorption capacity of 0.9%
saline of from 15 to 20g/100cm2.
saline of from 15 to 20g/100cm2.
13. A sterile freeze-dried sponge according to claim 1, wherein the sponge has a resorption time under simulated physiological conditions of more than 48 hours.
14. A method of manufacture of a freeze-dried sponge pad comprising the steps of:
providing an acidified paste of purified collagen fibers, wherein the collagen is less than 10% denatured;
providing oxidized regenerated cellulose fibers, wherein at least 80% of said fibers have lengths in the range of 20µm to 1000µm;
combining said collagen and said ORC fibers in a homogeneous aqueous dispersion in a weight ratio of 60:40 to 40:60 collagen:ORC, said aqueous dispersion being acidified to a pH in the range of 2.8 to 3.2 and having a total solids concentration of 0.8 to 1.2% by weight;
pouring said aqueous dispersion into trays to a depth greater than 1 cm;
freezing the dispersion to a temperature below -30°C, followed by a temperature programmed freeze drying and dehydrothermal cross-linking to a final moisture content of 5-15% by weight;
splitting the freeze-dried dispersion to remove surface layers and leave one or more pads; and sterilizing the one or more pads by gamma-irradiation.
providing an acidified paste of purified collagen fibers, wherein the collagen is less than 10% denatured;
providing oxidized regenerated cellulose fibers, wherein at least 80% of said fibers have lengths in the range of 20µm to 1000µm;
combining said collagen and said ORC fibers in a homogeneous aqueous dispersion in a weight ratio of 60:40 to 40:60 collagen:ORC, said aqueous dispersion being acidified to a pH in the range of 2.8 to 3.2 and having a total solids concentration of 0.8 to 1.2% by weight;
pouring said aqueous dispersion into trays to a depth greater than 1 cm;
freezing the dispersion to a temperature below -30°C, followed by a temperature programmed freeze drying and dehydrothermal cross-linking to a final moisture content of 5-15% by weight;
splitting the freeze-dried dispersion to remove surface layers and leave one or more pads; and sterilizing the one or more pads by gamma-irradiation.
15. A method according to claim 14 carried out substantially without the use of any chemical cross-linking agents.
16. A method according to claim 14, wherein the step of providing collagen comprises the following steps:
providing fresh and unswollen splits of bovine corium;
treating the splits with a hypochloride solution to inhibit microbial activity;
treating the corium with a solution containing sodium hydroxide and hydrogen peroxide to swell and sterilize the corium; then treating the corium with a aqueous alkali solution at a pH greater than 12 and temperature less than 50°C for a period of ten-fourteen days; then treating the corium with a aqueous acid solution at a pH of 0.8-1.2 and temperature less than 50°C; then washing the corium, and comminuting the corium with sufficient water to form a paste.
providing fresh and unswollen splits of bovine corium;
treating the splits with a hypochloride solution to inhibit microbial activity;
treating the corium with a solution containing sodium hydroxide and hydrogen peroxide to swell and sterilize the corium; then treating the corium with a aqueous alkali solution at a pH greater than 12 and temperature less than 50°C for a period of ten-fourteen days; then treating the corium with a aqueous acid solution at a pH of 0.8-1.2 and temperature less than 50°C; then washing the corium, and comminuting the corium with sufficient water to form a paste.
17. A method according to claim 14, wherein the step of providing oxidized regenerated cellulose fibers comprising milling an oxidized regenerated cellulose cloth and screening the milled particles to remove particles having size less than 20µm or greater than 1000µm.
18. A method according to claim 14, wherein the step of dispersing the collagen and the ORC comprises the steps of:
adding an acid-swollen collagen/water paste to acidified water;
adding oxidized regenerated cellulose fibers to the acidified water; and homogenizing the resulting mixture.
adding an acid-swollen collagen/water paste to acidified water;
adding oxidized regenerated cellulose fibers to the acidified water; and homogenizing the resulting mixture.
19. A method according to claim 14, wherein the step of freezing is carried out by placing the trays containing the aqueous dispersion onto chilled shelves in a freezer followed by holding the trays at a temperature below -30°C
until the freezing is complete.
until the freezing is complete.
20. A method according to claim 14, wherein the step of freeze drying is carried out with dehydrothermal cross-linking.
21. A method according to claim 14, wherein the step of sterilizing is carried out by gamma-irradiation at a dose of 18-29 KGy.
22. A method according to claim 14, wherein the weight ratio of collagen to oxidized regenerated cellulose is from 50:50 to 55:45 and the pH of the aqueous dispersion is from 2.9 to 3.1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/570,105 US6309454B1 (en) | 2000-05-12 | 2000-05-12 | Freeze-dried composite materials and processes for the production thereof |
| US09/570,105 | 2000-05-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2347331A1 CA2347331A1 (en) | 2001-11-12 |
| CA2347331C true CA2347331C (en) | 2010-07-13 |
Family
ID=24278241
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2347331A Expired - Lifetime CA2347331C (en) | 2000-05-12 | 2001-05-10 | Freeze-dried composite materials and processes for the production thereof |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US6309454B1 (en) |
| EP (1) | EP1153622B1 (en) |
| JP (1) | JP4799758B2 (en) |
| AU (1) | AU783184B2 (en) |
| CA (1) | CA2347331C (en) |
| DE (1) | DE60106322T2 (en) |
| GB (1) | GB2362466B (en) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1401352B1 (en) | 2001-06-14 | 2012-03-21 | Kenton W. Gregory | Method for producing a chitosan wound dressing |
| US8741335B2 (en) | 2002-06-14 | 2014-06-03 | Hemcon Medical Technologies, Inc. | Hemostatic compositions, assemblies, systems, and methods employing particulate hemostatic agents formed from hydrophilic polymer foam such as Chitosan |
| US7371403B2 (en) * | 2002-06-14 | 2008-05-13 | Providence Health System-Oregon | Wound dressing and method for controlling severe, life-threatening bleeding |
| US20030059460A1 (en) * | 2001-09-27 | 2003-03-27 | Yasuhiko Tabata | Hybrid material for regeneration of living body tissue |
| US8269058B2 (en) * | 2002-06-14 | 2012-09-18 | Hemcon Medical Technologies, Inc. | Absorbable tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan |
| US20050137512A1 (en) * | 2003-12-23 | 2005-06-23 | Campbell Todd D. | Wound dressing and method for controlling severe, life-threatening bleeding |
| US20070082023A1 (en) * | 2002-06-14 | 2007-04-12 | Hemcon Medical Technologies, Inc. | Supple tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan |
| AU2003263344B2 (en) | 2002-09-11 | 2009-01-08 | Johnson & Johnson Medical Limited | Wound dressing materials comprising complexes of anionic polysaccharides with silver |
| GB2392913B (en) * | 2002-09-11 | 2007-04-04 | Johnson & Johnson Medical Ltd | Wound dressings comprising complexes of oxidised celluloses with silver |
| US6863924B2 (en) * | 2002-12-23 | 2005-03-08 | Kimberly-Clark Worldwide, Inc. | Method of making an absorbent composite |
| EP1635850B1 (en) * | 2003-06-20 | 2008-08-13 | Johnson & Johnson Medical Ltd. | Antimicrobial silver comprising silver |
| GB2408206B (en) | 2003-11-18 | 2007-11-28 | Johnson & Johnson Medical Ltd | Antioxidant and antimicrobial wound dressing materials |
| GB0408492D0 (en) | 2004-04-16 | 2004-05-19 | Univ Strathclyde | Performance measurement of wound dressings |
| GB2414021A (en) * | 2004-05-10 | 2005-11-16 | Johnson & Johnson Medical Ltd | Absorbable haemostatic materials |
| US9204957B2 (en) | 2005-03-17 | 2015-12-08 | Hemcon Medical Technologies, Inc. | Systems and methods for hemorrhage control and or tissue repair |
| US20150328347A1 (en) | 2005-03-24 | 2015-11-19 | Xyleco, Inc. | Fibrous materials and composites |
| AU2013203464B2 (en) * | 2005-03-24 | 2015-10-08 | Xyleco, Inc. | Fibrous materials and composites |
| AU2015246115B2 (en) * | 2005-03-24 | 2017-11-16 | Xyleco, Inc. | Fibrous materials and composites |
| EP2564931B1 (en) * | 2005-03-24 | 2014-08-06 | Xyleco, Inc. | Methods of making fibrous materials |
| US20060286144A1 (en) * | 2005-06-17 | 2006-12-21 | Chunlin Yang | Reinforced collagen scaffold |
| GB2433029A (en) * | 2005-12-09 | 2007-06-13 | Ethicon Inc | Wound dressings comprising oxidized cellulose and human recombinant collagen |
| WO2007109137A1 (en) * | 2006-03-20 | 2007-09-27 | Worcester Polytechnic Institute | Fibrin microthreads |
| EP2026850B1 (en) | 2006-05-23 | 2014-07-09 | Providence Health System-Oregon d/b/a Providence St. Vincent Medical Center | Systems and methods for introducing and applying a bandage structure within a body lumen or hollow body organ |
| EP1945855B1 (en) * | 2006-09-12 | 2009-11-18 | MeadWestvaco Corporation | Paperboard containing microplatelet cellulose particles |
| GB2444232A (en) | 2006-11-30 | 2008-06-04 | Ethicon Inc | Wound dressing compositions comprising cell lysates |
| US20090004253A1 (en) * | 2007-06-29 | 2009-01-01 | Brown Laura J | Composite device for the repair or regeneration of tissue |
| AU2009241687A1 (en) * | 2008-05-02 | 2009-11-05 | Providence Health System-Oregon D/B/A Providence St. Vincent Medical Center | Wound dressing devices and methods |
| WO2010042540A1 (en) | 2008-10-06 | 2010-04-15 | Providence Health System - Oregon | Foam medical devices and methods |
| DE102008064510A1 (en) * | 2008-12-22 | 2010-06-24 | Paul Hartmann Aktiengesellschaft | Measuring apparatus for vacuum therapy systems for wound treatment |
| GB0912009D0 (en) | 2009-07-10 | 2009-08-19 | Univ Strathclyde | Sensor |
| WO2011116250A2 (en) * | 2010-03-17 | 2011-09-22 | Worcester Polytechnic Institute | Biopolymer microthreads with microscale surface topographies |
| DE102010037469A1 (en) * | 2010-09-10 | 2012-03-15 | Gelita Ag | A method of reducing endotoxin content in a collagen-containing material |
| GB201116523D0 (en) | 2011-09-23 | 2011-11-09 | Systagenix Wound Man Ip Co Bv | Wound prognosis |
| EP2896963B1 (en) | 2011-01-31 | 2019-01-30 | Woundchek Laboratories B.V. | Wound prognosis |
| EP2502964A1 (en) * | 2011-03-24 | 2012-09-26 | Molda AG | Method for manufacturing collagen |
| US8815832B2 (en) | 2012-05-25 | 2014-08-26 | Ethicon, Inc. | Oxidized regenerated cellulose hemostatic powders and methods of making |
| CA2928336C (en) | 2015-04-28 | 2020-08-18 | Frank Dicosmo | Bioactive collagen biomaterials and methods for making |
| EP3370783B1 (en) | 2015-11-06 | 2023-06-07 | Ethicon, Inc. | Compacted hemostatic cellulosic aggregates |
| CN108430526B (en) | 2015-11-08 | 2021-08-10 | 奥姆里克斯生物药品有限公司 | Hemostatic mixture of cellulose-based short and long fibers |
| AU2016366404A1 (en) | 2015-12-11 | 2018-06-14 | Lifecell Corporation | Methods and systems for stiffening of tissue for improved processing |
| WO2017172854A1 (en) | 2016-03-29 | 2017-10-05 | George Pins | Compositions and methods for wound healing |
| US11413335B2 (en) | 2018-02-13 | 2022-08-16 | Guangzhou Bioseal Biotech Co. Ltd | Hemostatic compositions and methods of making thereof |
| CN107754005B (en) | 2016-08-15 | 2021-06-15 | 广州倍绣生物技术有限公司 | Hemostatic compositions and methods of making same |
| CN106421884B (en) * | 2016-12-12 | 2019-09-24 | 西北大学 | The method that two step freezings prepare styptic sponge |
| KR102050879B1 (en) | 2017-08-11 | 2019-12-17 | 서울대학교 산학협력단 | Method of preparing short fibers, short fibers prepared by the method and use thereof |
| WO2019126368A1 (en) | 2017-12-20 | 2019-06-27 | Kci Usa, Inc. | Dressing including dehydrated placental tissue for wound healing |
| EP3823680B1 (en) | 2018-07-16 | 2024-03-06 | Systagenix Wound Management, Limited | Nitric oxide producing collagen/orc dressing |
| EP3843680B1 (en) | 2018-08-27 | 2023-10-04 | Systagenix Wound Management, Limited | Material application system for tunneling wounds that allows co-delivery of solutions |
| CN109673810B (en) * | 2018-12-20 | 2021-06-01 | 南京农业大学 | Regenerated cellulose-myofibrillar protein gel and preparation method thereof |
| EP3897759A1 (en) | 2018-12-21 | 2021-10-27 | KCI Licensing, Inc. | Wound dressings including pvp-citric acid copolymer |
| EP3990037A1 (en) | 2019-06-28 | 2022-05-04 | KCI Licensing, Inc. | Layered collagen dressing with extended bacteria and biofilm reducing capabilities |
| US20220354987A1 (en) | 2019-06-28 | 2022-11-10 | Systagenix Wound Management, Limited | Collagen polysaccharide wound dressing |
| CN115252889B (en) * | 2022-07-15 | 2023-07-25 | 武汉纺织大学 | Oxygen generating stent and preparation method thereof |
Family Cites Families (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3157524A (en) * | 1960-10-25 | 1964-11-17 | Ethicon Inc | Preparation of collagen sponge |
| GB1195061A (en) * | 1966-05-27 | 1970-06-17 | Fmc Corp | Coated Structures and Methods of Forming Them. |
| US3598622A (en) | 1969-02-19 | 1971-08-10 | Cpc International Inc | Alkali treated starch compositions |
| US3632350A (en) * | 1970-02-02 | 1972-01-04 | Fmc Corp | Food compositions containing microcrystalline collagen |
| US4265233A (en) | 1978-04-12 | 1981-05-05 | Unitika Ltd. | Material for wound healing |
| US4412947A (en) | 1979-09-12 | 1983-11-01 | Seton Company | Collagen sponge |
| DE2943520C2 (en) * | 1979-10-27 | 1982-05-19 | Fa. Carl Freudenberg, 6940 Weinheim | Process for the production of collagen sponge for medical or cosmetic purposes |
| DE8013626U1 (en) | 1980-05-21 | 1980-10-30 | Deutsche Semperit Gmbh, 8000 Muenchen | RUBBER OR PLASTIC PROFILE |
| CA1156529A (en) | 1980-06-12 | 1983-11-08 | Fred A. Serravallo | Fibrous collagenous hemostatic-adhesive webs |
| DE3037513C2 (en) | 1980-10-03 | 1983-05-05 | Steffan, Wolfgang, 8425 Neustadt | Collagen wound dressing |
| DE3105624A1 (en) | 1981-02-16 | 1982-09-02 | Hormon-Chemie München GmbH, 8000 München | MATERIAL FOR SEALING AND HEALING Wounds |
| EP0068047B1 (en) | 1981-06-25 | 1986-07-23 | Serapharm GmbH & Co. KG | Enriched plasma derivative for promoting wound sealing and wound healing |
| DE3136808A1 (en) | 1981-09-16 | 1983-03-31 | Bayer Ag, 5090 Leverkusen | TRIAZOLIDINE-3,5-DIONE |
| FR2516927B1 (en) | 1981-11-26 | 1986-05-23 | Merieux Fond | PROCESS FOR THE INDUSTRIAL PREPARATION OF COLLAGENIC MATERIALS FROM HUMAN PLACENTARY TISSUES, HUMAN COLLAGENIC MATERIALS OBTAINED, THEIR APPLICATION AS BIOMATERIALS |
| DE3212412C2 (en) | 1982-04-02 | 1986-01-02 | Dr. Ruhland Nachf. GmbH, 8425 Neustadt | Tissue-bondable collagen wound dressing |
| CA1209475A (en) | 1982-04-12 | 1986-08-12 | Mamerto M. Cruz, Jr. | Hemostatic-adhesive collagen dressing for severed biological surfaces |
| US5149332A (en) | 1982-06-30 | 1992-09-22 | Richard R. Walton | Absorbent and cushioning products and their manufacture |
| CA1212879A (en) | 1982-07-21 | 1986-10-21 | Laszlo Juhasz | Composite wound dressing |
| JPH0631316B2 (en) | 1982-08-04 | 1994-04-27 | ラ ジヨラ キヤンサ− リサ−チ フアンデイシヨン | Polypeptide |
| SE446688C (en) | 1982-09-14 | 1989-08-01 | Magnus Hoeoek | Means for the removal of microorganisms from tissues, which consist of a protein that can be bound to the microorganisms |
| DE3248188A1 (en) | 1982-12-27 | 1984-06-28 | Behringwerke Ag, 3550 Marburg | METHOD FOR PRODUCING A COLLAGEN FLEECE |
| US4474949A (en) | 1983-05-06 | 1984-10-02 | Personal Products Company | Freeze dried microfibrilar cellulose |
| GB2148901A (en) | 1983-10-04 | 1985-06-05 | Johnson & Johnson | Protein/polysaccharide complexes |
| US4515637A (en) | 1983-11-16 | 1985-05-07 | Seton Company | Collagen-thrombin compositions |
| DE3409372A1 (en) | 1984-03-14 | 1985-09-19 | Dr. Ruhland Nachf. GmbH, 8425 Neustadt | Material for the vitalisation of implant surfaces |
| GB8413319D0 (en) | 1984-05-24 | 1984-06-27 | Oliver Roy Frederick | Biological material |
| US4626253A (en) | 1984-10-05 | 1986-12-02 | Johnson & Johnson Products, Inc. | Surgical hemostat comprising oxidized cellulose |
| US4604346A (en) | 1984-10-09 | 1986-08-05 | Massachusetts Institute Of Technology | Skin-equivalent prepared by the use of punch biopsy |
| JPS61122222A (en) | 1984-11-19 | 1986-06-10 | Koken:Kk | Hemostatic agent composed of collagen or gelatin and protamine |
| US4600533A (en) | 1984-12-24 | 1986-07-15 | Collagen Corporation | Collagen membranes for medical use |
| JPS61253065A (en) | 1985-05-02 | 1986-11-10 | 片倉チツカリン株式会社 | Medical composite material of chitosan derivative and collagen and its production |
| DE3522626A1 (en) | 1985-06-25 | 1987-01-08 | Merz & Co Gmbh & Co | SOLUBLE COLLAGEN SPONGE |
| CS253042B1 (en) | 1985-09-25 | 1987-10-15 | Maxmilian Mozisek | Haemostatical material |
| DE3606265A1 (en) | 1986-02-27 | 1987-09-03 | Roehm Pharma Gmbh | POLYSACCHARID-BASED Wound Dressing As a Carrier Therapeutically Effective, Non-Immobilized Enzymes and with High Absorbency |
| NZ235556A (en) | 1986-11-05 | 1991-06-25 | Ethicon Inc | Breast milk substitute containing recombinant human egf |
| GB8705985D0 (en) | 1987-03-13 | 1987-04-15 | Geistlich Soehne Ag | Dressings |
| CS269876B1 (en) | 1987-06-22 | 1990-05-14 | Maryska Stanislav | Haemostatic non-absorbable therapeutical planary absorbent textile fabric |
| GB2208277B (en) | 1987-07-30 | 1991-11-13 | Courtaulds Plc | Cellulosic fibre |
| US4947840A (en) | 1987-08-21 | 1990-08-14 | Massachusetts Institute Of Technology | Biodegradable templates for the regeneration of tissues |
| NZ226171A (en) | 1987-09-18 | 1990-06-26 | Ethicon Inc | Gel formulation containing polypeptide growth factor |
| US4876332A (en) | 1987-10-08 | 1989-10-24 | Regents Of The Univeristy Of Minnesota | Polypeptides with type IV collagen activity |
| US5277915A (en) | 1987-10-30 | 1994-01-11 | Fmc Corporation | Gel-in-matrix containing a fractured hydrogel |
| JPH01130252A (en) | 1987-11-03 | 1989-05-23 | Internatl Business Mach Corp <Ibm> | Computer assembly connector |
| US4919681A (en) | 1988-02-16 | 1990-04-24 | Basf Corporation | Method of preparing cellulosic fibers having increased absorbency |
| AU632273B2 (en) | 1988-03-09 | 1992-12-24 | Terumo Kabushiki Kaisha | Medical material permitting cells to enter thereinto and artificial skin |
| DE68909933T2 (en) | 1988-03-09 | 1994-03-03 | Terumo Corp | FOR CELL-PULLABLE MEDICAL MATERIAL AND ARTIFICIAL SKIN. |
| US4950483A (en) | 1988-06-30 | 1990-08-21 | Collagen Corporation | Collagen wound healing matrices and process for their production |
| US5024841A (en) | 1988-06-30 | 1991-06-18 | Collagen Corporation | Collagen wound healing matrices and process for their production |
| US5110604A (en) | 1988-06-30 | 1992-05-05 | Collagen Corporation | Processes for producing collagen matrixes and methods of using same |
| DE3832162A1 (en) | 1988-09-22 | 1990-04-12 | Lohmann Therapie Syst Lts | METHOD FOR THE PRODUCTION OF COLLAGEN FOAMS IN THE FORM OF ENDLESS TAPES AND USE IN MEDICINE, COSMETICS AND HYGIENE |
| JP2719671B2 (en) | 1989-07-11 | 1998-02-25 | 日本ゼオン株式会社 | Wound dressing |
| US5124197A (en) | 1989-07-28 | 1992-06-23 | Kimberly-Clark Corporation | Inflated cellulose fiber web possessing improved vertical wicking properties |
| JPH03176064A (en) | 1989-12-05 | 1991-07-31 | Hoechst Japan Ltd | Wound surface covering material |
| SE9002017D0 (en) | 1990-06-06 | 1990-06-06 | Kabivitrum Ab | PROCESS FOR MANUFACTURE OF MATRICES |
| WO1991019470A1 (en) | 1990-06-14 | 1991-12-26 | Vitaphore Corporation | Polyurethane-biopolymer composite |
| CN1035803C (en) | 1990-07-24 | 1997-09-10 | 中国化工进出口总公司 | Soluble hemostyptic fabric |
| FR2667246A1 (en) | 1990-10-02 | 1992-04-03 | Imedex | BIOMATERIAL BASED ON COLLAGEN AND APPLICATIONS. |
| IT1249315B (en) | 1991-05-23 | 1995-02-22 | Euroresearch Srl | NON-POROUS COLLAGEN PLATE FOR THERAPEUTIC USE, METHOD AND EQUIPMENT TO OBTAIN IT |
| CA2071137A1 (en) | 1991-07-10 | 1993-01-11 | Clarence C. Lee | Composition and method for revitalizing scar tissue |
| CH683149A5 (en) | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Process for the preparation of microspheres of a biodegradable polymeric material. |
| GB9206509D0 (en) | 1992-03-25 | 1992-05-06 | Jevco Ltd | Heteromorphic sponges containing active agents |
| GB9206504D0 (en) | 1992-03-25 | 1992-05-06 | Jevco Ltd | Heteromorphic sponges as wound implants |
| GB2266239B (en) | 1992-03-25 | 1996-03-06 | Jevco Ltd | Wound healing compositions containing chondroitin sulphate oligosaccharides |
| DE4242015A1 (en) | 1992-04-02 | 1993-10-07 | Sebapharma Gmbh & Co | Wound dressing, wound dressing or carrier matrix |
| CA2094658A1 (en) | 1992-04-23 | 1993-10-24 | Martin Sumner-Smith | Intracellular delivery of biochemical agents |
| IL105529A0 (en) | 1992-05-01 | 1993-08-18 | Amgen Inc | Collagen-containing sponges as drug delivery for proteins |
| FR2692582B1 (en) | 1992-06-18 | 1998-09-18 | Flamel Tech Sa | NEW CROSSLINKABLE DERIVATIVES OF COLLAGEN, THEIR PROCESS FOR OBTAINING IT AND THEIR APPLICATION TO THE PREPARATION OF BIOMATERIALS. |
| DE4227681C2 (en) | 1992-08-21 | 1995-05-18 | Becker & Co Naturinwerk | Wound covering material based on collagen fibers and process for its production |
| US5679372A (en) | 1992-11-02 | 1997-10-21 | Yasuhiko Shimizu | Absorbable topical hemostat |
| US5491130A (en) | 1992-11-10 | 1996-02-13 | The United States Of America As Represented By The Department Of Health And Human Services | Peptide inhibitors of fibronectin and related collagen-binding proteins |
| GB2272645B8 (en) | 1992-11-23 | 2010-02-10 | Johnson & Johnson Medical | Wound dressing |
| GB9225581D0 (en) | 1992-12-08 | 1993-01-27 | Courtaulds Plc | Wound dressings |
| FR2699184B1 (en) | 1992-12-16 | 1995-03-10 | Flamel Tech Sa | New collagen derivatives, their process for obtaining and their application to the preparation of biomaterials. |
| GB2275686B (en) | 1993-03-03 | 1997-04-30 | Johnson & Johnson Medical | Swellable wound dressing materials |
| GB2280850B (en) | 1993-07-28 | 1997-07-30 | Johnson & Johnson Medical | Absorbable composite materials for use in the treatment of periodontal disease |
| GB2280372B (en) | 1993-07-28 | 1997-12-03 | Johnson & Johnson Medical | Composite surgical material |
| AT410754B (en) | 1993-03-31 | 2003-07-25 | Nycomed Austria Gmbh | DEVICE FOR EVENLY APPLYING A SUSPENSION TO A COLLAGE CARRIER |
| FR2704632B1 (en) | 1993-04-29 | 1995-06-23 | Air Liquide | PROCESS AND PLANT FOR SEPARATING AIR. |
| US5405953A (en) | 1993-08-03 | 1995-04-11 | Biocontrol Incorporated | Microfibrillated oxycellulose |
| JP3542170B2 (en) | 1993-08-06 | 2004-07-14 | 株式会社アムニオテック | Medical material and method for producing the same |
| DK94693D0 (en) | 1993-08-19 | 1993-08-19 | Coloplast As | NON-FIBROEST POROEST MATERIALS, SPECIAL BANDING INCLUDING SUCH A BANDAGE AND PROCEDURE FOR MANUFACTURING THE MATERIAL |
| GB2281861B (en) | 1993-09-21 | 1997-08-20 | Johnson & Johnson Medical | Bioabsorbable wound implant materials containing microspheres |
| US5441491A (en) | 1994-02-04 | 1995-08-15 | Verschoor; Jacob | Method and composition for treating biopsy wounds |
| DE4405175C2 (en) | 1994-02-18 | 1997-04-24 | Dt Membranfilter Vertrieb | Device for filtering and separating flow media by means of filter elements designed in the manner of membrane cushions |
| DE4407875C2 (en) | 1994-03-04 | 1996-04-04 | Ankerpharm Gmbh Ankerwerk Rudo | Medical sponge made from bioabsorbable materials, process and device for its production |
| US5599335A (en) | 1994-03-29 | 1997-02-04 | The Procter & Gamble Company | Absorbent members for body fluids having good wet integrity and relatively high concentrations of hydrogel-forming absorbent polymer |
| DE4414755C2 (en) | 1994-04-27 | 2000-11-16 | Lohmann Therapie Syst Lts | Collagen preparation for the controlled delivery of active ingredients, processes and use |
| FR2724951A1 (en) | 1994-09-26 | 1996-03-29 | Elysees Balzac Financiere | REGENERATED CELLULOSE-BASED MATERIALS WITH IMPROVED JAVEL WATER RESISTANCE AND PROCESS FOR THEIR PREPARATION |
| US5660854A (en) * | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
| EP0743066A3 (en) | 1995-05-16 | 1998-09-30 | Mitsui Pharmaceuticals, Inc. | Wound-healing agent |
| GB2301362B (en) | 1995-05-30 | 1999-01-06 | Johnson & Johnson Medical | Absorbable implant materials having controlled porosity |
| US5562645A (en) | 1995-05-31 | 1996-10-08 | Kimberly-Clark Corporation | Article with soft absorbent pulp sheet |
| US5677284A (en) | 1995-06-06 | 1997-10-14 | Regen Biologics, Inc. | Charged collagen particle-based delivery matrix |
| US5843852A (en) | 1995-12-21 | 1998-12-01 | Kimberly-Clark Worldwide, Inc. | Absorbent structure for liquid distribution |
| JP3476631B2 (en) | 1995-12-21 | 2003-12-10 | 株式会社アムニオテック | Medical material composed of human-derived natural collagen membrane |
| EP0837091A1 (en) | 1996-04-26 | 1998-04-22 | Toho Rayon Co., Ltd. | Cellulose sponge and method of manufacturing same |
| GB2314842B (en) | 1996-06-28 | 2001-01-17 | Johnson & Johnson Medical | Collagen-oxidized regenerated cellulose complexes |
| GB2314840B (en) | 1996-06-28 | 2000-09-06 | Johnson & Johnson Medical | Oxidized oligosaccharides and pharmaceutical compositions |
| FR2754268B1 (en) * | 1996-10-07 | 1998-12-24 | Dev Des Utilisations Du Collag | ADHESIVE COMPOSITION BASED ON MACROMOLECULAR POLYALDEHYDE AND METHOD FOR CROSSLINKING COLLAGEN OR GELATIN |
| US5824007A (en) | 1996-12-03 | 1998-10-20 | Simon Fraser University | Adjustable surgical stand |
| JPH10212690A (en) * | 1997-01-23 | 1998-08-11 | Oji Paper Co Ltd | Low-density body |
| FR2760644B1 (en) | 1997-03-13 | 2000-01-28 | Cosmetique De Lecousse Lab | COLLAGEN COMPOSITION, PROCESS FOR THE PREPARATION THEREOF AND APPLICATIONS THEREOF |
| GB2329181B (en) | 1997-09-11 | 2002-03-13 | Johnson & Johnson Medical | Bioabsorbable Wound Dressing Materials |
| US5985434A (en) | 1997-11-25 | 1999-11-16 | Kimberly-Clark Worldwide, Inc. | Absorbent foam |
-
2000
- 2000-05-12 US US09/570,105 patent/US6309454B1/en not_active Expired - Lifetime
-
2001
- 2001-02-27 US US09/793,825 patent/US20010045177A1/en not_active Abandoned
- 2001-03-23 GB GB0107400A patent/GB2362466B/en not_active Expired - Lifetime
- 2001-05-10 CA CA2347331A patent/CA2347331C/en not_active Expired - Lifetime
- 2001-05-10 AU AU43806/01A patent/AU783184B2/en not_active Expired
- 2001-05-11 JP JP2001142179A patent/JP4799758B2/en not_active Expired - Lifetime
- 2001-05-11 DE DE60106322T patent/DE60106322T2/en not_active Expired - Lifetime
- 2001-05-11 EP EP01304248A patent/EP1153622B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1153622A1 (en) | 2001-11-14 |
| AU783184B2 (en) | 2005-09-29 |
| JP2002058733A (en) | 2002-02-26 |
| DE60106322D1 (en) | 2004-11-18 |
| GB2362466B (en) | 2003-10-08 |
| US6309454B1 (en) | 2001-10-30 |
| CA2347331A1 (en) | 2001-11-12 |
| DE60106322T2 (en) | 2005-10-27 |
| GB2362466A (en) | 2001-11-21 |
| AU4380601A (en) | 2001-11-15 |
| EP1153622B1 (en) | 2004-10-13 |
| JP4799758B2 (en) | 2011-10-26 |
| GB0107400D0 (en) | 2001-05-16 |
| US20010045177A1 (en) | 2001-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2347331C (en) | Freeze-dried composite materials and processes for the production thereof | |
| US7098315B2 (en) | Method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge | |
| CA2435159C (en) | A method of preparing a collagen sponge | |
| CN107233613B (en) | Aquatic organism source cross-linked collagen composite multilayer medical dressing | |
| RU2369408C2 (en) | Hemostatic composition comprising hyaluronic acid | |
| US20140010887A1 (en) | Modified starch material of biocompatible hemostasis | |
| CN111905143B (en) | Multifunctional tissue adhesion crystal gel dressing and preparation method and application thereof | |
| WO2019038548A1 (en) | Psyllium based moisture absorbent material | |
| WO2017122216A1 (en) | A process for extraction of collagen from fish scale and polyelectrolyte based bioactive super-absorbent materials | |
| AU2002249528A1 (en) | A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge | |
| Zhang et al. | A low-swelling and toughened adhesive hydrogel with anti-microbial and hemostatic capacities for wound healing | |
| CN107551312B (en) | Flocculent collagen hemostatic fiber and preparation method thereof | |
| CN111870732B (en) | Hemostatic particles capable of inducing tissue regeneration and repair and preparation method and application thereof | |
| Chen et al. | Expandable, biodegradable, bioactive quaternized gelatin sponges for rapidly controlling incompressible hemorrhage and promoting wound healing | |
| CN109498833A (en) | A kind of Medical absorbable polysaccharide composite material and application thereof | |
| Valipour et al. | Preparation and characterization of wound healing hydrogel based on fish skin collagen and chitosan cross-linked by dialdehyde starch | |
| CN114225113B (en) | Degradable artificial dura mater with double-layer structure and preparation method thereof | |
| TWI526488B (en) | Chemical crosslinking composition, bio-medical material containing the same and use of the same | |
| CN112516175A (en) | Cuttlebone treatment method, cuttlebone product and hemostasis and healing promotion material | |
| CN115227878B (en) | Silver-loaded type-I collagen composite material and preparation method and application thereof | |
| RU2780089C1 (en) | Biodegradable protein-polysaccharide film with immobilized enzyme trypsin for use as a wound coating | |
| JP2005013457A (en) | Molding obtained from fish-derived collagen and its thermal denaturation material | |
| CN117323461A (en) | Hemostatic material and preparation method thereof | |
| CN117414462A (en) | Hemostatic granule for diffuse hemorrhage and preparation method and application thereof | |
| CN114618007A (en) | Preparation method of wound plaster containing human collagen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20210510 |